PolyPid Ltd.
PYPD•NASDAQ•Healthcare•Biotechnology

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Company Information

SectorHealthcare
IndustryBiotechnology
CEODikla Czaczkes Akselbrad
Founded2008
IPO DateJune 26, 2020
Employees60
CountryIsrael
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.polypid.com
Phone972 7 4719 5700
Address
18 Hasivim Street Petah Tikva, 4959376 Israel

Corporate Identifiers

CIK0001611842
CUSIPM8001Q118
ISINIL0011326795
SIC3841

Leadership Team & Key Executives

Dalit Hazan
Deputy Chief Executive Officer and Executive Vice President of Research & Development, Clinical and Regulatory Affairs
Dikla Czaczkes Akselbrad
Chief Executive Officer and Director
Jonny Missulawin
Chief Financial Officer
Ori Warshavsky
Chief Operating Officer - US
Maria Rubin
Executive Vice President of Operations
Tal Vilnai
General Counsel and Corporate Secretary
Rivi Lev-ari
Vice President of Human Resource
Dr. Jean-Marc Hagai Pharm.D.
Chief Commercial Officer
Dr. Nurit Tweezer-Zaks M.B.A., M.D.
Chief Medical Officer